Phase 1 interim results showed an excellent immunogenicity profile after a single-shot vaccination and an acceptable safety profile, supporting further development

  • 100% seroconversion rate achieved at Day 28 after a single-shot vaccination in a pooled analysis of all dose groups
  • Pooled analysis showed a high antibody response based on geometric mean titre
  • No serious adverse events or adverse events of special interest were reported up to Day 28